Therapeutic implications of melanoma heterogeneity
Open Access
- 8 April 2016
- journal article
- viewpoint
- Published by Wiley in Experimental Dermatology
- Vol. 25 (7) , 497-500
Abstract
Over the last decade, the treatment of metastatic melanoma has been revolutionized by the translation of molecular insights into therapeutic benefit for patients. These include advances in immunotherapeutic and small‐molecule approaches aimed at destroying cells with immunogenic antigens or gene mutations. Despite these advances, the limited durability of clinical response and eventual disease progression underscores a need for better understanding of mechanisms underlying tumor development. Current targeted therapies are developed partly based on the rationale that tumors are primarily clonal with respect to mutant oncogene or cell surface antigen target. However, with the advancement of cell isolation and transplantation approaches coupled with deep sequencing and mutation detection techniques, it has become increasingly clear that tumors are polyclonal. As a result, sensitive malignant cells are eradicated by treatment while the remaining tumor cell populations are conferred varying degrees of resistance and survival advantages by harbouring or acquiring certain epigenetic and genetic abnormalities. Tumor heterogeneity thus represents a major obstacle to the successful application of current therapies. Gaining insights into the cellular and molecular aspects of tumor diversity will not only facilitate the development and selection of therapeutic targets but also promote the evolution of precision medicine. In this viewpoint, we will discuss the implications of tumor heterogeneity for the treatment of metastatic melanoma and propose approaches to accelerate the translation of scientific discovery into improved clinical outcomes.Keywords
Funding Information
- Melanoma Research Alliance (440850‐41635)
This publication has 73 references indexed in Scilit:
- A Landscape of Driver Mutations in MelanomaCell, 2012
- VEGFR-1 Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor GrowthCancer Research, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically OrganizedCancer Cell, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271Nature, 2010
- Modulation of T-Cell Activation by Malignant Melanoma Initiating CellsCancer Research, 2010
- A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 2009
- Efficient tumour formation by single human melanoma cellsNature, 2008
- Identification of cells initiating human melanomasNature, 2008